Novel approaches and future directions in castration-resistant prostate cancer

被引：16

作者：

Nabhan, C. ^{[1
]}

Parsons, B. ^{[1
]}

Touloukian, E. Z. ^{[2
]}

Stadler, W. M. ^{[3
]}

机构：

[1] Lutheran Gen Hosp, Div Hematol & Oncol, Dept Med, Park Ridge, IL 60068 USA

[2] Providence Hosp, Dept Med, Southfield, MI 48037 USA

[3] Univ Chicago, Dept Med, Chicago, IL 60637 USA

来源：

ANNALS OF ONCOLOGY | 2011年 / 22卷 / 09期

关键词：

angiogenesis; castration resistant; immunotherapy; immunomodulatory agents; prostate cancer; receptor antagonists; PHASE-II TRIAL; ENDOTHELIAL GROWTH-FACTOR; MITOXANTRONE PLUS PREDNISONE; RANDOMIZED CONTROLLED-TRIAL; SIPULEUCEL-T APC8015; ABIRATERONE ACETATE; MONOCLONAL-ANTIBODY; IMATINIB MESYLATE; CLINICAL-TRIALS; FACTOR RECEPTOR;

D O I：

10.1093/annonc/mdq639

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Recent advances in the treatment of castration-resistant prostate cancer (CRPC) have started to change the therapeutic landscape allowing clinicians to choose from a broad range of treatment options. Understanding the mechanisms that transform prostate cancer (PCA) into a castration-resistant state has enabled investigators to explore critical pathways involved in such process allowing for rational therapeutic design. These novel therapies complement the modest success that chemotherapy has demonstrated in recent years. In this review, we discuss the different mechanisms that render PCA castration resistant and elaborate on the nonchemotherapy approaches evolving in CRPC. These include agents targeting the epidermal growth factor receptor, endothelin receptor antagonists, angiogenesis inhibitors, immunomodulatory agents, immunotherapy, novel antiandrogens, and delivery of cytotoxic agents via therapeutic antibodies. This timely review coincides with the identification of newer therapies in this setting affirming our steady movement towards better disease control.

引用

页码：1948 / 1957

页数：10

共 127 条

[1] Sorafenib (BAY 43-9006, Nexavar®), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature [J].

Adnane, Lila ;

Trail, Pamela A. ;

Taylor, Ian ;

Wilhelm, Scott M. .

REGULATORS AND EFFECTORS OF SMALL GTPASES: RAS FAMILY, 2006, 407 :597-+

[2] Phase 2 study of granulocyte-macrophage colony-stimulating factor plus thalidomide in patients with hormone-naive adenocarcinoma of the prostate [J].

Amato, Robert J. ;

Hernandez-McClain, Joan ;

Henary, Haby .

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2009, 27 (01) :8-13

[3] Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer [J].

Aragon-Ching, Jeanny B. ;

Jain, Lokesh ;

Gulley, James L. ;

Arlen, Philip M. ;

Wright, John J. ;

Steinberg, Seth M. ;

Draper, David ;

Venitz, Juergen ;

Jones, Elizabeth ;

Chen, Clara C. ;

Figg, William D. ;

Dahut, William L. .

BJU INTERNATIONAL, 2009, 103 (12) :1636-1640

[4] A Phase I-II Study of Docetaxel and Atrasentan in Men with Castration-Resistant Metastatic Prostate Cancer [J].

Armstrong, Andrew J. ;

Creel, Patricia ;

Turnbull, James ;

Moore, Cassandra ;

Jaffe, Tracy A. ;

Haley, Sherri ;

Petros, William ;

Yenser, Sarah ;

Gockerman, Jon P. ;

Sleep, Darryl ;

Hurwitz, Herbert ;

George, Daniel J. .

CLINICAL CANCER RESEARCH, 2008, 14 (19) :6270-6276

[5] Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer [J].

Attard, Gerhardt ;

Reid, Alison H. M. ;

A'Hern, Roger ;

Parker, Christopher ;

Oommen, Nikhil Babu ;

Folkerd, Elizabeth ;

Messiou, Christina ;

Molife, L. Rhoda ;

Maier, Gal ;

Thompson, Emilda ;

Olmos, David ;

Sinha, Rajesh ;

Lee, Gloria ;

Dowsett, Mitch ;

Kaye, Stan B. ;

Dearnaley, David ;

Kheoh, Thian ;

Molina, Arturo ;

de Bono, Johann S. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (23) :3742-3748

[6] Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen [J].

Bander, NH ;

Nanus, DM ;

Milowsky, MI ;

Kostakoglu, L ;

Vallabahajosula, S ;

Goldsmith, SJ .

SEMINARS IN ONCOLOGY, 2003, 30 (05) :667-677

[7] Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa [J].

Berthold, D. R. ;

Pond, G. R. ;

de Wit, R. ;

Eisenberger, M. ;

Tannock, I. F. .

ANNALS OF ONCOLOGY, 2008, 19 (10) :1749-1753

[8] Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study [J].

Berthold, Dominik R. ;

Pond, Gregory R. ;

Soban, Freidele ;

de Wit, Ronald ;

Eisenberger, Mario ;

Tannock, Ian F. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (02) :242-245

[9] Growth factor receptor tyrosine kinase inhibitors; Clinical development and potential for prostate cancer therapy [J].

Blackledge, G .

JOURNAL OF UROLOGY, 2003, 170 (06) :S77-S83

[10] Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3K/AKT activation [J].

Bonaccorsi, L ;

Marchiani, S ;

Muratori, M ;

Forti, G ;

Baldi, E .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2004, 130 (10) :604-614

← 1 2 3 4 5 6 7 8 9 10 →